CD47 and neoplasm: As a result, these anti-CD47 antibodies maintain favorable phagocytosis of tumor cells facilitated by CD47 blocking, but exhibit a minimal to negligible amount of RBC related on-target off-tumor effect in preclinical in vitro and in vivo development (65–67).